TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35970815

Group type: EXPERIMENTAL
Intervention: Antibiotic treatment (n=203)
Number of subjects: 408

Group type: COMPARATOR
Intervention: No antibiotic treatment (n=360)
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Rifaximin treatment (specific numbers not provided)
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Long-term antibiotic prophylaxis at discharge (specific numbers not provided)
Number of subjects: 408
Study: 34425901

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Tell-Show-Do (TSD)
Number of subjects: 120
Study: 32319076

Group type: EXPERIMENTAL
Intervention: Levodopa inhalation powder 84 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 34754306

Group type: EXPERIMENTAL
Intervention: 10% capsaicin paste (EP group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Water (Control group)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: High-load tasks
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Low-load tasks
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Cognitive load increase
Number of subjects: 40
Study: 33168104

Group type: COMPARATOR
Intervention: 15 days before lockdown
Number of subjects: 27

Group type: COMPARATOR
Intervention: 15 days during lockdown
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 15 days after lockdown
Number of subjects: 27
Study: 35559243

Group type: EXPERIMENTAL
Intervention: Low dose of ziprasidone (60–80 mg/d) in combination with sertraline
Number of subjects: 62

Group type: COMPARATOR
Intervention: Usual dose of ziprasidone (120–160 mg/d) monotherapy
Number of subjects: 62
Study: 33041018

Group type: EXPERIMENTAL
Intervention: Cross-Education (n = 11)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Traditional Training (n = 11)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (n = 10)
Number of subjects: 32
Study: 33785385

Group type: EXPERIMENTAL
Intervention: Imiquimod treatment
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 40
Study: 35322843

Group type: EXPERIMENTAL
Intervention: Cranberry (9 g powder solubilized in water equivalent to 100 g of fresh cranberries, 525 mg total (poly)phenols)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control (9 g powder, no (poly)phenols)
Number of subjects: 45
Study: 34567223

Group type: EXPERIMENTAL
Intervention: Peppermint essential oil (3 drops inhaled for 7 nights)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Lavender essential oil (3 drops inhaled for 7 nights)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control (3 drops of aromatic placebo inhaled for 7 nights)
Number of subjects: 105
Study: 34644472

Group type: EXPERIMENTAL
Intervention: Cell-culture-derived quadrivalent inactivated influenza vaccine (IIV4c)
Number of subjects: 4514

Group type: COMPARATOR
Intervention: Meningococcal ACWY vaccine (control)
Number of subjects: 4514

Group type: EXPERIMENTAL
Intervention: IIV4c
Number of subjects: 4514
Study: 32675750

Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 948

Group type: COMPARATOR
Intervention: Ticagrelor
Number of subjects: 948
Study: 34983147

Group type: EXPERIMENTAL
Intervention: Breastfeeding immediately before heel lance (group 1)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Breastfeeding one hour before heel lance (group 2)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Breastfeeding two hours before heel lance (group 3)
Number of subjects: 91
Study: 34131001

Group type: EXPERIMENTAL
Intervention: Crossover veliparib monotherapy (300-400 mg twice daily continuous)
Number of subjects: 513

Group type: EXPERIMENTAL
Intervention: Crossover veliparib monotherapy
Number of subjects: 513
Study: 35366806

Group type: EXPERIMENTAL
Intervention: Single-use bronchoscopes (SUB, Ambu aScope)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Reusable bronchoscopes (CONV, Olympus BF-P60)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Cost analysis for single-use bronchoscopes (SUB)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Cost analysis for reusable bronchoscopes (CONV)
Number of subjects: 46
Study: 33754156

Group type: EXPERIMENTAL
Intervention: Immediate nicotine reduction (VLNC cigarettes)
Number of subjects: 1250

Group type: EXPERIMENTAL
Intervention: Gradual nicotine reduction (VLNC cigarettes)
Number of subjects: 1250

Group type: COMPARATOR
Intervention: Control condition (normal nicotine content cigarettes)
Number of subjects: 1250
Study: 32157678

Group type: EXPERIMENTAL
Intervention: Individually customized tapering plan at discharge combined with telephone counselling one week after discharge
Number of subjects: 110

Group type: COMPARATOR
Intervention: No tapering plan or telephone counselling
Number of subjects: 110
Study: 35248915

Group type: EXPERIMENTAL
Intervention: Kaleidoscope
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study: 32707905

Group type: EXPERIMENTAL
Intervention: High amylose noodles (45% amylose)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Low amylose noodles (15% amylose)
Number of subjects: 12
Study: 35908869

Group type: COMPARATOR
Intervention: PCV13 (13-valent pneumococcal vaccine)
Number of subjects: 245
Study: 34221185

Group type: EXPERIMENTAL
Intervention: Five-gene signature (TENM1, FN1, APOD, F12, BTNL8)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nomogram based on gene expression and clinical characteristics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Risk score and distant metastasis (M)
Number of subjects: 0
Study: 32702912

Group type: EXPERIMENTAL
Intervention: High-intensity pelvic floor muscle training (PFMT) 5 times a week for 30 minutes per day for 12 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-intensity pelvic floor muscle training (PFMT) twice a week for 15 minutes per day for 12 weeks
Number of subjects: 0
Study: 33492719

Group type: COMPARATOR
Intervention: Normal PT (≤12.7 s)
Number of subjects: 1524

Group type: EXPERIMENTAL
Intervention: Extremely prolonged PT (≥17.3 s)
Number of subjects: 1524

Group type: EXPERIMENTAL
Intervention: Slightly prolonged PT (12.8≤PT≤15.0 s)
Number of subjects: 1524

Group type: EXPERIMENTAL
Intervention: Intermediately prolonged PT (15.1≤PT≤17.2 s)
Number of subjects: 1524
Study: 34021097

Group type: EXPERIMENTAL
Intervention: LEA + EX (15 kcal·kg fat-free mass-1·day-1)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: LEA - EX (15 kcal·kg fat-free mass-1·day-1)
Number of subjects: 6

Group type: COMPARATOR
Intervention: CON + EX
Number of subjects: 6

Group type: COMPARATOR
Intervention: CON - EX
Number of subjects: 6
Study: 33350994

Group type: EXPERIMENTAL
Intervention: Caffeinated energy dietary supplement (55 mg of caffeine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33645308

Group type: EXPERIMENTAL
Intervention: GP endorsement on the letter accompanying the guaiac faecal occult blood testing kit
Number of subjects: 394842

Group type: COMPARATOR
Intervention: Usual letter
Number of subjects: 394842
Study: 32026506

Group type: EXPERIMENTAL
Intervention: Telehealth educational intervention (4 sessions over 12 weeks)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 92
Study: 34735004

Group type: EXPERIMENTAL
Intervention: Cre8 EVO stents
Number of subjects: 1175

Group type: COMPARATOR
Intervention: Resolute Onyx stents
Number of subjects: 1175
Study: 34147867

Group type: EXPERIMENTAL
Intervention: 3 minute step test (3MST1)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 3 minute step test (3MST2)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 3 minute step test (3MST)
Number of subjects: 30
Study: 34661562

Group type: EXPERIMENTAL
Intervention: Smart pill bottle reminder intervention for 4 weeks
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 61
Study: 33595885

Group type: EXPERIMENTAL
Intervention: Excimer light and topical calcipotriol
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Topical calcipotriol monotherapy
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Calcipotriol-based regimen
Number of subjects: 26

Group type: COMPARATOR
Intervention: Clobetasol-based regimen
Number of subjects: 26
Study: 32901654

Group type: EXPERIMENTAL
Intervention: Forced air circulation chamber (40.18 °C, 28.48% RH) for drying
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Silica gel desiccator (27.19 °C, 26.19% RH) for drying
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Refrigerator at 5 °C for storage
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Freezer at -20 °C for storage
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Room temperature (29 °C) with previous drying for storage
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Room temperature (29 °C) without drying for storage
Number of subjects: 100
Study: 36282407

Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS); 18 sessions (twice a week for nine weeks)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Sham stimulation (control group)
Number of subjects: 56
Study: 34404588

Group type: EXPERIMENTAL
Intervention: Elastic traction + Distraction Osteogenesis
Number of subjects: 70

Group type: COMPARATOR
Intervention: Distraction Osteogenesis
Number of subjects: 70
Study: 35482651

Group type: EXPERIMENTAL
Intervention: Behaviorally based weight-loss treatments (BBWLTs)
Number of subjects: 191
Study: 32558218

Group type: EXPERIMENTAL
Intervention: Orbital atherectomy (OA)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Orbital atherectomy (OA) plus balloon angioplasty
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Drug-eluting stents after OA
Number of subjects: 87
Study: 33143547

Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg/kgBW)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 34001423

Group type: EXPERIMENTAL
Intervention: Theory of Planned Behavior
Number of subjects: 232
Study: 32046537

Group type: EXPERIMENTAL
Intervention: Whole-body hot pack thermal therapy (HPTT)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Waon therapy (WT)
Number of subjects: 19
Study: 34626578

Group type: EXPERIMENTAL
Intervention: C-reactive protein point-of-care testing (CRP POCT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Initial training and training of new employees for CRP POCT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Facilitators for implementation of CRP POCT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall quality of CRP POCT implementation
Number of subjects: 0
Study: 33021348

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 926

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 926
Study: 35797653

Group type: EXPERIMENTAL
Intervention: Endoscopic Facet Joint Denervation (EG)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Percutaneous Facet Joint Denervation (PG)
Number of subjects: 40
Study: 34078097

Group type: EXPERIMENTAL
Intervention: FFR-guided CABG
Number of subjects: 100

Group type: COMPARATOR
Intervention: Angiography-guided CABG
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Graft failure or FFR<0.80
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Graft failure or low FFR in deferred lesions
Number of subjects: 100
Study: 34537184

Group type: EXPERIMENTAL
Intervention: Left atrial appendage occlusion (LAAO) using Amplatzer Amulet or Watchman FLX with lifelong aspirin 75 mg daily
Number of subjects: 750

Group type: COMPARATOR
Intervention: Novel oral anticoagulants (NOACs)
Number of subjects: 750
Study: 32556718

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR)
Number of subjects: 502
Study: 35879205

Group type: EXPERIMENTAL
Intervention: V-flap technique
Number of subjects: 20

Group type: COMPARATOR
Intervention: Slit-arteriotomy technique
Number of subjects: 20
Study: 33055462

Group type: EXPERIMENTAL
Intervention: TIV + PPSV23 (simultaneous inoculations of TIV and PPSV23)
Number of subjects: 40

Group type: COMPARATOR
Intervention: TIV + Placebo (inoculations of TIV and placebo)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 32577745

Group type: EXPERIMENTAL
Intervention: Levothyroxine (starting with 50 μg, adjusted for weight and coronary heart disease)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Placebo (mock titration)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Levothyroxine (in participants with higher fatigability at baseline)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Placebo (in participants with higher fatigability at baseline)
Number of subjects: 230
Study: 35212924

Group type: EXPERIMENTAL
Intervention: Trastuzumab+Pertuzumab (TP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paclitaxel+Trastuzumab+Pertuzumab (PTP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paclitaxel+Trastuzumab+Pertuzumab with macrophage depletion (PTP+C)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trastuzumab+Pertuzumab with macrophage depletion (TP+C)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (Cremophor)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Analysis of TAM infiltrate in PTP, TP+C, and PTP+C
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clodronate depletion
Number of subjects: 0
Study: 34525007

Group type: EXPERIMENTAL
Intervention: PCV20
Number of subjects: 460

Group type: COMPARATOR
Intervention: PCV13
Number of subjects: 460
Study: 36071444

Group type: EXPERIMENTAL
Intervention: Step-up arm: Intra-articular corticosteroid injection (IACI) in all affected joints for less severe oligoarthritis; IACI and methotrexate for polyarthritis or severe oligoarthritis.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Step-down arm: 6-month early combined treatment (methotrexate plus IACI for less severe oligoarthritis; methotrexate plus etanercept for severe oligoarthritis and polyarthritis).
Number of subjects: 0
Study: 34058112

Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bisoprolol
Number of subjects: 0
Study: 35277771

Group type: EXPERIMENTAL
Intervention: eTEP repair
Number of subjects: 60

Group type: COMPARATOR
Intervention: IPOM repair
Number of subjects: 60
Study: 34250940

Group type: EXPERIMENTAL
Intervention: Cognitive training (CT) for 12 weeks
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Cognitive training (CT)
Number of subjects: 37
Study: 34714502

Group type: EXPERIMENTAL
Intervention: Preventive Parenting Program (7 sessions)
Number of subjects: 191

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 191
Study: 34309839

Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula (HFNC) at 70 L min−1
Number of subjects: 40

Group type: COMPARATOR
Intervention: Face mask with 7 cm H2O of PEEP
Number of subjects: 40
Study: 32127550

Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Ecologic Femi+ vaginal capsule
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Gynophilus LP vaginal tablet
Number of subjects: 68

Group type: COMPARATOR
Intervention: Behavioral counseling only (control)
Number of subjects: 68
Study: 34312086

Group type: EXPERIMENTAL
Intervention: Reiki
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Back Massage
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control
Number of subjects: 102
Study: 32038104

Group type: EXPERIMENTAL
Intervention: Sufentanil
Number of subjects: 86

Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 86
Study: 35603644

Group type: EXPERIMENTAL
Intervention: COMPASS transitional care (COMPASS‐TC)
Number of subjects: 5882

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 5882
Study: 33430957

Group type: EXPERIMENTAL
Intervention: Computer-based cognitive training intervention using Attentive Rehabilitation of Attention and Memory (ARAM) software, 45 minutes per session, twice a week for 10 sessions.
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Computer-based cognitive training intervention
Number of subjects: 52

Group type: COMPARATOR
Intervention: Educational workshops (control group)
Number of subjects: 52
Study: 33411550

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Didactic educational counseling (DEC)
Number of subjects: 27
Study: 34229709

Group type: EXPERIMENTAL
Intervention: Task-sharing with community health workers for screening and pre-referral management of pre-eclampsia/eclampsia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Community health workers trained to identify basic danger signs of pregnancy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthcare facility preparedness
Number of subjects: 0

Group type: COMPARATOR
Intervention: Access to ambulances for referrals
Number of subjects: 0
Study: 34623488

Group type: EXPERIMENTAL
Intervention: Supervised aerobic exercise program for 6 months
Number of subjects: 59

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 59
Study: 35346115

Group type: EXPERIMENTAL
Intervention: CALM program (integrated lifestyle program)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Psychotherapy (cognitive behavioural therapy)
Number of subjects: 184
Study: 34008127

Group type: EXPERIMENTAL
Intervention: GMM-based tests for mediated effects
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional tests
Number of subjects: 0
Study: 33371483

Group type: EXPERIMENTAL
Intervention: 2S-Hesperidin 500 mg/day
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (microcellulose) 500 mg/day
Number of subjects: 40
Study: 35150142

Group type: EXPERIMENTAL
Intervention: D‐β‐hydroxybutyrate esters (KE) drink with 395 mgKE/kg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo drink
Number of subjects: 12
Study: 34279663

Group type: EXPERIMENTAL
Intervention: HbA1c ≥ 8.0% in lowest tertile of glucose CV
Number of subjects: 6090

Group type: EXPERIMENTAL
Intervention: HbA1c ≥ 8.0% in middle tertile of glucose CV
Number of subjects: 6090

Group type: COMPARATOR
Intervention: HbA1c 6.0%-6.9% in lowest and middle tertiles of glucose CV
Number of subjects: 6090

Group type: EXPERIMENTAL
Intervention: HbA1c in highest tertile of glucose CV
Number of subjects: 6090
Study: 36198482

Group type: EXPERIMENTAL
Intervention: SEDLine monitoring during induction of anesthesia
Number of subjects: 0
Study: 33755184

Group type: EXPERIMENTAL
Intervention: Sleep (overnight sleep with polysomnography)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Wake (daytime wake from 09:00 am to 21:00 pm)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: N3 sleep post-encoding
Number of subjects: 98
Study: 35357314

Group type: EXPERIMENTAL
Intervention: Unreliable source with protective message
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Unreliable source without protective message
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Reliable source with protective message
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Reliable source without protective message
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: No identified source with protective message
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: No identified source without protective message
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Protective message
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Type of source and protective message interaction
Number of subjects: 307
Study: 36264097

Group type: EXPERIMENTAL
Intervention: Actovegin (1200 mg daily, intravenously for two weeks, followed by oral administration for 10 weeks)
Number of subjects: 366

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 366
Study: 33038289

Group type: EXPERIMENTAL
Intervention: Deutetrabenazine 15 mg (fed state)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Deutetrabenazine 7.5, 15, and 22.5 mg (repeated dosing)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Deutetrabenazine 6, 12, 18, and 24 mg (with standard meal)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Deutetrabenazine 18 mg (with high-fat meal)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Deutetrabenazine (any dose)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Tetrabenazine 25 mg (fasted state)
Number of subjects: 32
Study: 34338086

Group type: EXPERIMENTAL
Intervention: Brief online cognitive training intervention for threat interpretations
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 98
Study: 33887492

Group type: EXPERIMENTAL
Intervention: Fibrin glue sealant (2 ml per 100 cm2 surface area)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (only drain placement)
Number of subjects: 32
Study: 35645781

Group type: EXPERIMENTAL
Intervention: Sport stacking intervention (30 min, 5 days/week for 12 weeks)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Active control group (not specified)
Number of subjects: 48
Study: 33189655

Group type: EXPERIMENTAL
Intervention: Plasma IGFBP7
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: GSMR analysis of IGFBP7
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Causal mediation analysis of IGFBP7
Number of subjects: 300
Study: 35523943

Group type: EXPERIMENTAL
Intervention: Tolcapone (200 mg t.i.d.)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Tolcapone
Number of subjects: 90
Study: 33148308

Group type: EXPERIMENTAL
Intervention: Rescue intervention strategy (RIS) with budesonide/formoterol plus original treatment until AQI < 200
Number of subjects: 72

Group type: COMPARATOR
Intervention: Original treatment (no inhaled medicine, SABA on demand, or budesonide/formoterol 160 μg/4.5 μg/dose, 1–2 dose/time, b.i.d.)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Rescue intervention strategy (RIS)
Number of subjects: 72
Study: 36098814

Group type: EXPERIMENTAL
Intervention: Clindamycin (600 mg) administered 1 hour before surgery
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 33963974

Group type: EXPERIMENTAL
Intervention: LOAGB‐OSPAN
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: LMGB‐OAGB
Number of subjects: 60

Group type: COMPARATOR
Intervention: HDER
Number of subjects: 60
Study: 35045567

Group type: EXPERIMENTAL
Intervention: Oral alendronate (ALN) 70 mg weekly for 52 weeks
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 34029455

Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (250 mg every 4 weeks)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Control group (no testosterone treatment)
Number of subjects: 106